November 4th, 2010
CardioExchange and the Ethos of Community
Harlan M. Krumholz, MD, SM
We recently posted a blog that described the experience of a Fellow whose assessment of a patient and the need for a test was not seemingly given the fullest attention by the attending physician. Many of us remember such experiences in our training and the sense that there were issues beyond the patient that were […]
November 1st, 2010
ROCKET AF: Is Rivaroxaban Ready for Blast Off?
Harlan M. Krumholz, MD, SM
With the approval of dabigatran and now the preliminary and partial results of ROCKET AF, we’ll need to be familiar with much more than just warfarin to address the anticoagulation needs of our patients. The early word on ROCKET AF, which will be presented at AHA, is that rivaroxaban is at least as effective as warfarin […]
October 1st, 2010
A Case of Exuberance About a Subgroup in a Clinical Trial
Harlan M. Krumholz, MD, SM
In many clinical trials, researchers investigate whether an overall effect of an intervention is consistent across various subgroups, as I discussed in this Journal Club Series last week. Such subgroup analyses require assessment of what is called an interaction — that is, whether the effect in one group differs from that in another. Do the benefits differ, […]
September 26th, 2010
Avandia: Lessons Learned and Unanswered Questions
Harlan M. Krumholz, MD, SM
The following is republished from Pharmalot, a widely read site that provides commentary on the pharmaceutical industry and related litigation. What should we make of the decisions on Avandia yesterday? There remains some controversy about the risk, but the concerns were sufficient, given the therapeutic alternatives, to bring about action. The Europeans decided to suspend sales […]
September 19th, 2010
A Rich OASIS for Your Journal Club
Harlan M. Krumholz, MD, SM
I’m always scouting for papers to discuss in journal club with my students. Earlier this month, I found the perfect pair: two simultaneously published articles from the industry-funded CURRENT–OASIS 7 randomized trial, one in the New England Journal of Medicine and the other in the Lancet. Many of the authors of the two papers were […]
August 25th, 2010
Is There a Generation Gap in Cardiology?
Larry Husten, PHD, Harlan M. Krumholz, MD, SM, L. David Hillis, MD and Andrew M. Kates, MD
A brief posting in the Wall Street Journal Health Blog on the clash of generations in the medical workplace recently caught our attention. The Blog summarizes a commentary by Sharon Phelan in Obstetrics & Gynecology, which posits that “different attitudes about work and life held by members of different generations can create tensions and clashes in the […]
August 3rd, 2010
Building on Your Success
Harlan M. Krumholz, MD, SM
Welcome to the remodeled CardioExchange: We hope you like our new look! In our efforts to develop a website that promotes learning and discussion about our rapidly evolving field, we’ve been listening and learning. We have many new features. Some of the most prominent are: You can now see all of the activity on the site from the […]
July 26th, 2010
Questions for Sanjay Kaul about TIDE and Avandia
Sanjay Kaul, MD and Harlan M. Krumholz, MD, SM
CardioExchange’s editor-in-chief Harlan Krumholz discussed the TIDE trial on email with Sanjay Kaul, who was a member of the FDA’s advisory panel last week on Avandia. Here is a lightly edited version of their exchange. Krumholz: What is your response to the FDA announcement that it has placed TIDE on a “partial clinical hold”? Do you […]
January 3rd, 2010
Top Cardiology Stories of 2009
Harlan M. Krumholz, MD, SM
Dear Readers, This year the annual Journal Watch Cardiology Top Stories feature has a new dimension. We are presenting two lists — one from us and one from you. To create the Journal Watch Cardiology 2009: Editors’ Choice list, our editors voted for the stories that they believe to be most important to you and your […]
January 3rd, 2010
CardioExchange in 2010
Harlan M. Krumholz, MD, SM
Happy New Year! On behalf of everyone at CardioExchange, I want to thank you for being part of our experiment. I hope that all of you have seen the potential for what a community of cardiologists led by a group of independent experts can do to improve patient care. CardioExchange is still very much a work […]